Notes in Prostate

To Subscribe, use this Key

Status	Last Update	Fields
Published	02/18/2024	MRS \| Prostate \| 3.2.2 \| RP vs. RT vs. AS \| ProtecT \| NEJM 2016
Published	02/18/2024	MRS \| Prostate \| 1.1 \| Anatomy
Published	02/18/2024	MRS \| Prostate \| 1.2 \| Epidemiology
Published	02/18/2024	MRS \| Prostate \| 1.3.1 \| Aetiology / risk factors
Published	02/18/2024	MRS \| Prostate \| 1.4 \| Pathologic classification
Published	02/18/2024	MRS \| Prostate \| 1.5 \| Pre-malignant lesions
Published	02/18/2024	MRS \| Prostate \| 1.6.1 \| Adenocarcioma - acinar variant
Published	02/18/2024	MRS \| Prostate \| 1.7.1 \| Grading
Published	02/18/2024	MRS \| Prostate \| 1.7.2 \| Significance of Gleason score
Published	02/18/2024	MRS \| Prostate \| 1.7.3 \| Advantages of Gleason grading system
Published	02/18/2024	MRS \| Prostate \| 1.7.4 \| Gleason score - difficulties in grading
Published	02/18/2024	MRS \| Prostate \| 1.6.2 \| IHC to distinguish benign and malignant prostate
Published	02/18/2024	MRS \| Prostate \| 1.8.2 \| PSA
Published	02/18/2024	MRS \| Prostate \| 2.1 \| Workup
Published	02/18/2024	MRS \| Prostate \| 2.2 \| Staging (AJCC 8th edition 2017)
Published	02/18/2024	MRS \| Prostate \| 2.3.1 \| NCCN risk stratification
Published	02/18/2024	MRS \| Prostate \| 2.4 \| Prognostic factors
Published	02/18/2024	MRS \| Prostate \| 2.3.2 \| Other risk stratification tools
Published	02/18/2024	MRS \| Prostate \| 2.3.3 \| Predicting organ confined cancer (RP sutiability)
Published	02/18/2024	MRS \| Prostate \| 2.3.4 \| Natural history \| Albertsen data (JAMA, 2005)
Published	02/18/2024	MRS \| Prostate \| 2.5 \| Screening
Published	02/18/2024	MRS \| Prostate \| 3.1 \| Management \| Overview
Published	02/18/2024	MRS \| Prostate \| 3.2.1 \| Approach
Published	02/18/2024	MRS \| Prostate \| 3.3 \| Observation / 'Watchful waiting' / 'Palliative'
Published	02/18/2024	MRS \| Prostate \| 3.4 \| Active surveillance
Published	02/18/2024	MRS \| Prostate \| 3.5.1 \| Surgery
Published	02/18/2024	MRS \| Prostate \| 3.5.2.1 \| Postop RT \| Adjuvant (N0)
Published	02/18/2024	MRS \| Prostate \| 3.5.2.2 \| Postop RT \| Salvage
Published	02/18/2024	MRS \| Prostate \| 3.5.2.3 \| Postop RT \| Adjuvant vs. early salvage
Published	02/18/2024	MRS \| Prostate \| 3.6.2.1 \| Definitive EBRT \| Dose escalation
Published	02/18/2024	MRS \| Prostate \| 3.6.1 \| Definitive EBRT \| Efficacy
Published	02/18/2024	MRS \| Prostate \| 3.6.3 \| Definitive EBRT \| IMRT vs. 3DCRT
Published	02/18/2024	MRS \| Prostate \| 3.6.4 \| Definitive EBRT \| Moderate hyopfractionation
Published	02/18/2024	MRS \| Prostate \| 3.6.5 \| Definitive EBRT \| Extreme hypofractionation (SBRT)
Published	02/18/2024	MRS \| Prostate \| 3.6.6 \| Definitive EBRT \| Pelvic nodal RT
Published	02/18/2024	MRS \| Prostate \| 3.6.7 \| Definitive EBRT \| Node positive disease
Published	02/18/2024	MRS \| Prostate \| 3.7.1 \| ADT \| Overview
Published	02/18/2024	MRS \| Prostate \| 3.7.2 \| ADT \| Agents
Published	02/18/2024	MRS \| Prostate \| 3.7.3 \| ADT \| Toxicity
Published	02/18/2024	MRS \| Prostate \| 3.7.4 \| ADT \| Favourable intermediate risk (FIR)
Published	02/18/2024	MRS \| Prostate \| 3.7.6 \| ADT \| High risk
Published	02/18/2024	MRS \| Prostate \| 3.7.5 \| ADT \| Unfavourable intermediate risk (UIR)
Published	02/18/2024	MRS \| Prostate \| 3.7.8 \| ADT \| Further controversies
Published	02/18/2024	MRS \| Prostate \| 3.7.7 \| ADT \| Node positive
Published	02/18/2024	MRS \| Prostate \| 2.6 \| Definition of biochemical failure after definitive RT
Published	02/18/2024	MRS \| Prostate \| 4.2 \| RT technique \| Adjuvant / Salvage RT
Published	02/18/2024	MRS \| Prostate \| 4.1 \| RT technique \| Definitive RT
Published	02/18/2024	MRS \| Prostate \| 5.1 \| LDR brachytherapy
Published	02/18/2024	MRS \| Prostate \| 5.2 \| HDR brachytherapy
Published	02/18/2024	MRS \| Prostate \| 6.1 \| M+/Relapse \| ADT Redistribute in to PSA relapse and hormone-sensitive metastatic disease
Published	02/18/2024	MRS \| Prostate \| 7.1 \| Metastatic \| Hormone-sensitive metastatic disease
Published	02/18/2024	MRS \| Prostate \| 3.8 \| Very high risk \| Docetaxel (+ EBRT + ADT)
Published	02/18/2024	MRS \| Prostate \| 7.2 \| Metastatic \| Hormone-refractory prostate cancer Line up with NCCN
Published	02/18/2024	MRS \| Prostate \| 7.3 \| Metastatic \| Oligometastatic disease *STOMP, ORIOLE trials
Published	02/18/2024	MRS \| Prostate \| 8.1 \| To do
Published	02/18/2024	PET/CT  (inlcuding PSMA)
Published	02/18/2024	1 \| Prostate super summary (definitive)
Published	02/18/2024	MRS \| Prostate \| 1.8.1 \| Clinical presentation
Published	02/18/2024	MRS \| Prostate \| 3.5.3 \| pN1 disease
Published	02/18/2024	MRS \| Prostate \| 3.5.2.0 \| Biochemical failure or high risk post prostatectomy
Published	02/18/2024	2 \| Prostate super summary PPRT
Published	02/18/2024	Natural history of biochemical failure
Published	02/18/2024	MRS \| Prostate \| 2.1.3 \| PSMA PET
Published	02/18/2024	MRS \| Prostate \| 3.6.2.2 \| Definitive EBRT \| Dose escalation part 2 \| Focal boost
Published	02/18/2024	MRS \| Prostate \| 2.1.2 \| Biopsy techniques
Published	02/18/2024	MRS \| Prostate \| 1.7.1.2 \| Grading \| Differences  between RP and biopsy grading
Published	02/18/2024	MRS \| Prostate \| 5 \| Brachytherapy \| Indications
Status	Last Update	Fields